Paper: Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II Hematology Disease Topics & Pathways: Research, Acute Myeloid Malignancies, AML, Adult, Translational Research, MPN, Drug development, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Myeloid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, Animal model Zhe Wang, MD, PhD 1 *, Anna Skwarska, PhD 2, Gowri Poigailwar 2 *, Sovira